|
Immunology Studies 2015
sTNFRII-gAD-Fc融合蛋白在CHO细胞中的高效表达
|
Abstract:
[1] | Fernandez-Botran, R. (2000) Soluble cytokine receptors: Novel immunotherapeutic agents. Expert Opinion on Investi-gational Drugs, 9, 497-514. |
[2] | Mohler, K.M., Torrance, D.S., Smith, C.A., et al. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonistss. The Journal of Immunology, 151, 1548-1561. |
[3] | Edwards 3rd, C.K., Martin, S.W., Seely, J., et al. (2003) Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Advanced Drug Delivery Reviews, 55, 1315-1336. |
[4] | Combs, T.P., Wagner, J.A., Berger, J., et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: A potential mechanism of insulin sensitization. Endocrinology, 143, 998-1007. |
[5] | 高基民 (2007) 可溶性肿瘤坏死因子受体II-“脂联素”球部融合蛋白. 中国专利:200510100468.9. |
[6] | 陈素云, 何秋山, 董小岩 (2010) 可溶性肿瘤坏死因子受体II-脂联素球部融合蛋白的真核表达及生物学活性检测. 生物工程学报, 2, 207-215. |
[7] | 陆月, 刘丹, 张孝任 (2011) 腺病毒载体介导的重组蛋白sTNFRII-gAD快速表达和制备. 生物工程学报, 27, 1239-1246. |
[8] | Jia, Q., Wu, H. and Zhou, X. (2010) A “GC-rich” method for mammalian gene expression: A dominant role of non- coding DNA GC content in regulation of mammalian gene expression. Science China Life Sciences, 53, 94-100. |
[9] | 张翊, 高凯, 韩春梅 (2003) 重组人肿瘤坏死因子受体-Fc融合蛋白质控方法和标准的研究. 药学学报, 3, 165- 168. |
[10] | Luo, M., Liu, D. and Zhang, L. (2012) Protective effects of a novel trimerized sTNFRII on acute liver injury. International Immunopharmacology, 13, 88-92. |
[11] | Rosser, M.P., Xia, W. and Hartsell, S. (2005) Transient transfection of CHO-K1-S using serum-free medium in suspension: A rapid mammalian protein expression system. Protein Expression and Purification, 40, 237-243. |
[12] | Thomas, C.E., Ehrhardt, A. and Kay, M.A. (2003) Progress and problems with the use of viral vectors for gene therapy. Nature Reviews Genetics, 4, 346-358. |
[13] | Kurano, N., Leist, C. and Messi, F. (1990) Growth behavior of Chinese hamster ovary cells in a compact loop bioreactor: 1. Effects of physical and chemical environments. Journal of Biotechnology, 15, 101-112. |
[14] | Ozturk, S.S. and Palsson, B.O. (1991) Physiological changes during the adaption of hybridoma cells to low serum and serum-free media. Biotechnology and Bioengineering, 37, 35-46. |
[15] | Bibila, T.A. and Robinson, D.K. (1995) In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnology Progress, 11, 1-13. |
[16] | Hesse, F. and Wagner, R. (2000) Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. Trends in Biotechnology, 18, 173-180. |
[17] | Fletcher, T. (2005) Designing culture media for recombinant protein production: A rational approach. BioProcess International, 3, 30-36. |
[18] | Li, F., Hashimura, Y. and Pendleton, R. (2006) A systematic approach for scale-down model development and characterization of commercial cell culture processes. Biotechnology Progress, 22, 696-703. |
[19] | Spens, E. and H?ggstr?m, L. (2007) Defined protein and animal component-Free NS0 fed-batch culture. Biotechnology and Bioengineering, 98, 1183-1194. |
[20] | Xie, L.Z. and Wang, D.I.C. (1996) High cell density and high monoclonal antibody production through medium design and rational control in a bioreactor. Biotechnology and Bioengineering, 51, 725-729. |
[21] | Fox, S.R., Tan, H.K. and Tan, M.C. (2005) A detailed understanding of the enhanced hypothermic productivity of interfere on-gamma by Chinese-hamster ovary cells. Biotechnology and Applied Biochemistry, 41, 255-264. |
[22] | Fox, S.R., Yap, M.X. and Yap, M.G. (2005) Active hypothermic growth: A novel means for increasing total interferon- gamma production by Chinese-hamster ovary cells. Biotechnology and Applied Biochemistry, 41, 265-272. |